Recent reports on the superiority of prostate-specific membrane antigen (PSMA)–targeted PET imaging over the conventional modalities for prostate cancer at initial staging and recurrence have increased interest in exploring its utility for RCC (7–9). The gene discussed is FOLH1; the disease is prostate cancer.